



L-Uffiċċju tal-Uffiċjal Mediku Ewlieni

Office of the Chief Medical Officer

DH CIRCULAR No. 354/2013
DH 3625/2013

18 November 2013

Attention All: Consultants
Medical Officers
Pharmacists
Pharmacy Technicians
Nurses

Re: Ciprofloxacin Suspension

Ciprofloxacin 250mg/5mL granules for oral suspension have been recommended by the Government Formulary List Advisory Committee and approved by the Superintendent of Public Health for introduction onto the Government Formulary List.

Ciprofloxacin is a fluoroquinolone antibacterial active against both Gram-positive and Gram-negative bacteria.

Ciprofloxacin 250mg/5mL suspension protocol- regulated with protocol number 37 (attached). Consultants can prescribe ciprofloxacin for the indications described in the protocol

Ciprofloxacin 250mg/5mL suspension has been procured through the Central Procurement and Supplies Unit and is now available for use.

Dr Natasha Azzopardi Muscat
Chief Medical Officer

Ciprofloxacin 250mg/5mL Suspension

Prescriber Criteria: Consultant

Out-patient and In-patient use:

1. Cystic Fibrosis

To be reserved for paediatric patients with Pseudomonal lower respiratory tract infections in cystic fibrosis.

The use in children under 1 year requires endorsement by Consultant Infectious Disease Paediatrician.

Duration of Approval: 1 year

In-patient use:

1. Adult patients unable to swallow tablet form
2. Paediatric patients with:
 - Complicated urinary tract infections
 - Other infections where the benefit is considered to outweigh the potential risks (after endorsement by antibiotic team consultant)

The use in children under 1 year requires endorsement by Consultant Infectious Disease Paediatrician